Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT06533579 is registered in ClinicalTrials.gov with Vironexis Biotherapeutics Inc. as lead sponsor.

NCT NCT06533579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Lead sponsor
Vironexis Biotherapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2025
Completion date
September 30, 2031
Enrollment
32 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, burkitt lymphoma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, large b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, mixed phenotype acute leukemia, non hodgkin lymphoma, primary mediastinal large b-cell lymphoma (pmbcl), small lymphocytic lymphoma